Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Clene (CLNN)
NASDAQ:CLNN
Holding CLNN?
Track your performance easily
CLNN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.82 - $12.00
Previous Close$6.11
Volume31.05K
Average Volume (3M)136.03K
Market Cap
$47.69M
Enterprise Value$54.32M
Total Cash (Recent Filing)$21.68M
Total Debt (Recent Filing)$27.35M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Nov 05, 2024EPS Estimate
-$1.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding6,470,067
10 Day Avg. Volume46,736
30 Day Avg. Volume136,035
Standard Deviation0.29
R-Squared0.01
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-76.38
Price to Sales (P/S)89.44
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue122.89
Enterprise Value/Gross Profit101.91
Enterprise Value/Ebitda-2.29
Forecast
1Y Price Target
$50.00Price Target Upside734.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Clene News
PremiumCompany Announcements
Clene Unveils Phase 3 Trial Design at NEALS
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe study plans to enroll approximately 560 ALS patients, who are within 36 months of onset at the time of screening, and present ≥60% predicted vital capacity.
Financial StabilityCLNN recently closed a registered direct offering and amended a debt agreement, which means the company now has a cash runway into 1Q25.
Regulatory ApprovalAnalyst recommends a BUY rating, highlighting the potential to submit a new drug application (NDA) for CNM-Au8 for ALS via the accelerated approval pathway.
Bears Say
Capital RequirementsClene likely needs to raise capital to continue operations, but the outcome of the FDA meeting and a potential filing are seen as catalysts to drive shares and financing.
Financial RisksThe potential need to conduct a full Phase 3 trial prior to NDA submission could bring financing-related risks to the fore.
Regulatory ChallengesThe FDA rejected CNM-Au8’s current data package as being sufficient for a filing for an Accelerated Approval for treating amyotrophic lateral sclerosis (ALS).
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CLNN FAQ
What was Clene’s price range in the past 12 months?
Clene lowest stock price was $3.82 and its highest was $12.00 in the past 12 months.
What is Clene’s market cap?
Currently, no data Available
When is Clene’s upcoming earnings report date?
Clene’s upcoming earnings report date is Nov 05, 2024 which is tomorrow.
How were Clene’s earnings last quarter?
Clene released its earnings results on Aug 07, 2024. The company reported -$1.06 earnings per share for the quarter, beating the consensus estimate of -$1.508 by $0.448.
Is Clene overvalued?
According to Wall Street analysts Clene’s price is currently Undervalued.
Does Clene pay dividends?
Clene does not currently pay dividends.
What is Clene’s EPS estimate?
Clene’s EPS estimate is -$1.33.
How many shares outstanding does Clene have?
Clene has 7,962,100 shares outstanding.
What happened to Clene’s price movement after its last earnings report?
Clene reported an EPS of -$1.06 in its last earnings report, beating expectations of -$1.508. Following the earnings report the stock price went down -23.469%.
Which hedge fund is a major shareholder of Clene?
Currently, no hedge funds are holding shares in CLNN
---
Clene Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.00 (734.72% Upside)
$50.00 (734.72% Upside)
Blogger Sentiment
Bullish
CLNN Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $583.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.12%
12-Months-Change
Fundamentals
Return on Equity
-289.66%
Trailing 12-Months
Asset Growth
-40.56%
Trailing 12-Months
Company Description
Clene
Clene is a clinical-stage biopharma company focused on developing and commercializing nanotherapeutics for the treatment of neurodegenerative disease.
---
CLNN Stock 12 Month Forecast
Average Price Target
$50.00
▲(734.72% Upside)
Technical Analysis
Annovis Bio
―
Anavex Life Sciences
―
Brainstorm Cell Therapeutics
―
Cyclacel Pharmaceuticals
―
Best Analysts Covering CLNN
1 Year
1 Year Success Rate
3/16 ratings generated profit
1 Year Average Return
-24.87%
reiterated a buy rating 13 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -24.87% per trade.
---